We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise being 1.6%.
The Zacks Consensus Estimate for revenues is pinned at $4.1 billion, up 4.3% on a year-over-year basis.
Research and Development Solutions (R&DS) revenues are anticipated to be $2.2 billion, up marginally from the year-ago reported figure. Improved win rate, mainly in the emerging biopharma segment, is likely to have benefited R&DS’s revenues.
We expect revenues from Technology and Analytics Solutions to be $1.7 billion, indicating 8.5% growth on a year-over-year basis. Clients’ commercial road map strategies and new drug launches are expected to have aided this segment.
Our estimate for Contract sales and Medical solutions’ revenues is pinned at $181.7 million, implying a marginal growth from the year-ago quarter’s actual.
We expect the third quarter’s adjusted EBITDA to be $945.3 million, up marginally year over year.
The consensus estimate for earnings per share is pegged at $2.96, indicating 4.2% year-over-year growth. Strong cost control is anticipated to have improved the bottom line.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -0.11% and a Zacks Rank of 4 (Sell) at present.
Stocks to Consider
Here are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Alnylam Pharmaceuticals (ALNY - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2025 revenues is pegged at $1 billion, indicating more than 100% year-over-year growth. For earnings, the consensus mark is pegged at $1.67 per share, suggesting a more than 100% upsurge from the year-ago quarter’s reported figure. The company beat the consensus estimate in three of the past four quarters and met once, with an average surprise of 348.4%.
The company is scheduled to declare its third-quarter 2025 results on Oct. 30.
Adaptive Biotechnologies (ADPT - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2025 revenues is pegged at $62.2 million, suggesting growth of 33.9% from the year-ago quarter’s actual. For earnings, the consensus estimate for a loss is pegged at 16 cents per share compared with a loss of 22 cents in the year-ago quarter. ADPT beat the consensus estimate in each of the four quarters, with an average earnings surprise of 24%.
ADPT has an Earnings ESP of +29.17% and a Zacks Rank of 3 at present. The company is scheduled to declare its third-quarter 2025 results on Nov. 5.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?
Key Takeaways
IQVIA Holdings Inc. (IQV - Free Report) is set to release its third-quarter 2025 results on Oct. 28, before market open.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise being 1.6%.
IQVIA Holdings Inc. Price and EPS Surprise
IQVIA Holdings Inc. price-eps-surprise | IQVIA Holdings Inc. Quote
IQVIA’s Q3 Expectations
The Zacks Consensus Estimate for revenues is pinned at $4.1 billion, up 4.3% on a year-over-year basis.
Research and Development Solutions (R&DS) revenues are anticipated to be $2.2 billion, up marginally from the year-ago reported figure. Improved win rate, mainly in the emerging biopharma segment, is likely to have benefited R&DS’s revenues.
We expect revenues from Technology and Analytics Solutions to be $1.7 billion, indicating 8.5% growth on a year-over-year basis. Clients’ commercial road map strategies and new drug launches are expected to have aided this segment.
Our estimate for Contract sales and Medical solutions’ revenues is pinned at $181.7 million, implying a marginal growth from the year-ago quarter’s actual.
We expect the third quarter’s adjusted EBITDA to be $945.3 million, up marginally year over year.
The consensus estimate for earnings per share is pegged at $2.96, indicating 4.2% year-over-year growth. Strong cost control is anticipated to have improved the bottom line.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -0.11% and a Zacks Rank of 4 (Sell) at present.
Stocks to Consider
Here are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Alnylam Pharmaceuticals (ALNY - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2025 revenues is pegged at $1 billion, indicating more than 100% year-over-year growth. For earnings, the consensus mark is pegged at $1.67 per share, suggesting a more than 100% upsurge from the year-ago quarter’s reported figure. The company beat the consensus estimate in three of the past four quarters and met once, with an average surprise of 348.4%.
ALNY carries an Earnings ESP of +25.79% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company is scheduled to declare its third-quarter 2025 results on Oct. 30.
Adaptive Biotechnologies (ADPT - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2025 revenues is pegged at $62.2 million, suggesting growth of 33.9% from the year-ago quarter’s actual. For earnings, the consensus estimate for a loss is pegged at 16 cents per share compared with a loss of 22 cents in the year-ago quarter. ADPT beat the consensus estimate in each of the four quarters, with an average earnings surprise of 24%.
ADPT has an Earnings ESP of +29.17% and a Zacks Rank of 3 at present. The company is scheduled to declare its third-quarter 2025 results on Nov. 5.